<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(FINAL AMENDMENT)*
AMYLIN PHARMACEUTICALS, INC.
(Name of Issuer)
COMMON STOCK
(Title of Class of Securities)
032346 10 8
(CUSIP Number)
James J. Bergin, Esq.
Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933
(723) 524-2383
(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)
August 28, 2000
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G
to report the acquisition which is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(b)(3) or (4), check the following
box.
/ /
NOTE: Six copies of this statement, including all exhibits, should be filed with
the Commission. See Rule 13d-1(a) for other parties to whom copies are to be
sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
Page 1 of 6 Pages
<PAGE> 2
SCHEDULE 13D
---------------------- -----------------
CUSIP NO. 032346 10 8 PAGE 2 OF 6 PAGES
---------------------- -----------------
-------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Johnson & Johnson 22-1024240
-------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a)
/ /
(b)
/ /
-------------------------------------------------------------------------------
3 SEC USE ONLY
-------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
AF
-------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) or 2(e) / /
-------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
New Jersey
-------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
SHARES
BENEFICIALLY -0-
OWNED BY
EACH
REPORTING
PERSON
WITH
---------------------------------------------------------
8 SHARED VOTING POWER
3,105,857
---------------------------------------------------------
9 SOLE DISPOSITIVE POWER
-0-
---------------------------------------------------------
10 SHARED DISPOSITIVE POWER
3,105,857
-------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,105,857
-------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
/ /
-------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
4.94%
-------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
-------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION.
<PAGE> 3
SCHEDULE 13D
------------------------- -----------------
CUSIP NO. 032346 10 8 PAGE 3 OF 6 PAGES
------------------------- -----------------
-------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Johnson & Johnson Development Corporation 22-2007137
-------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a)
/ /
(b)
/ /
-------------------------------------------------------------------------------
3 SEC USE ONLY
-------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
WC
-------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) or 2(e) / /
-------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
New Jersey
-------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
SHARES
BENEFICIALLY -0-
OWNED BY
EACH
REPORTING
PERSON
WITH
---------------------------------------------------------
8 SHARED VOTING POWER
3,105,857
---------------------------------------------------------
9 SOLE DISPOSITIVE POWER
-0-
---------------------------------------------------------
10 SHARED DISPOSITIVE POWER
3,105,857
-------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,105,857
-------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
/ /
-------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
4.94%
-------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
-------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION.
<PAGE> 4
CUSIP 032346 10 8 Page 4 of 6 Pages
Final Amendment to Schedule 13D
This Statement amends Item 5 of the Statement on Schedule 13D (the
"Schedule 13D") relating to the shares of Common Stock, $.001 par value, of
Amylin Pharmaceuticals, Inc., a Delaware corporation (the "Company") originally
filed with the Securities and Exchange Commission on October 6, 1995 by Johnson
& Johnson ("J&J") and Johnson & Johnson Development Corporation ("JJDC"), both
New Jersey corporations. Capitalized terms used but not otherwise defined herein
have the same meaning as in the Schedule 13D.
Item 5. Interest in Securities of the Issuer:
Item 5 is hereby amended by deleting the information in Item 5
of the Schedule 13D and substituting in lieu the information
below.
(a) As of the date hereof, J&J and JJDC each had
beneficial ownership of an aggregate 3,105,857 shares
of Common Stock, which constituted approximately
4.94% of the outstanding shares of Common Stock of
the Company. The percentage amount set forth above is
based upon the number of shares of Common Stock
issued and outstanding as of August 4, 2000, as
reported in the Company's Quarterly Report on Form
10-Q for the quarter ended June 30, 2000.
(b) J&J and JJDC each have shared power to vote and
shared power to dispose of all shares described in
paragraph (a) above.
(c) There were no transactions in the Common Stock of the
Company effected by J&J during the past sixty days.
Set forth below is a list of the transactions in the
Common Stock of the Company effected by JJDC since
Amendment No. 4 to the Schedule 13D was filed. Each
transaction was a sale of Common Stock affected over
the counter through a broker:
<TABLE>
<CAPTION>
TRADE DATE # SHARES PRICE/ SHARE
------------------------------------------------------------------------------
<S> <C> <C>
02/24/00 17,500 $13.2500
02/28/00 5,000 $14.0000
02/29/00 40,000 $14.0156
03/01/00 140,000 $15.2143
03/03/00 85,000 $16.5662
03/06/00 100,000 $17.3969
03/07/00 15,000 $17.8750
06/21/00 25,000 $12.5000
06/22/00 25,000 $13.5000
</TABLE>
<PAGE> 5
CUSIP 032346 10 8 Page 5 of 6 Pages
<TABLE>
<S> <C> <C>
08/14/00 5,000 $14.0625
08/16/00 10,000 $13.5938
08/17/00 5,000 $13.6250
08/21/00 10,000 $13.6875
08/22/00 10,000 $14.0125
08/23/00 17,500 $14.1964
08/24/00 52,500 $14.0381
08/25/00 65,000 $13.9538
08/28/00 20,000 $13.9375
08/29/00 22,500 $13.4167
08/30/00 10,000 $13.3750
08/31/00 45,000 $13.5000
09/01/00 30,000 $13.5938
09/05/00 25,000 $14.0000
09/06/00 27,500 $13.3977
09/07/00 50,000 $13.6363
</TABLE>
To the best knowledge of J&J and JJDC, no director or
executive officer of J&J or JJDC beneficially owns
any shares of Common Stock or other securities of the
Company. Neither J&J nor JJDC is aware of any other
transaction in such securities during the past sixty
(60) days by any of its executive officers or
directors.
(d) Not applicable.
(e) JJDC sold approximately one percent (1%) of the
Common Stock on August 28, 2000. The Reporting
persons ceased to be the owner of more than five
percent (5%) of the Common Stock on September 7,
2000, when the percentage of Common Stock
beneficially held by the Reporting Persons was
reduced to four point nine four percent (4.94%) of
the outstanding Common Stock. The percentage amounts
set forth above are based upon the number of shares
of Common Stock issued and outstanding as of August
4, 2000, as reported in the Company's Quarterly
Report on Form 10-Q for the quarter ended June 30,
2000. Consequently, this is a final amendment to the
Schedule 13D.
<PAGE> 6
CUSIP 032346 10 8 Page 6 of 6 Pages
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true,
complete and correct.
JOHNSON & JOHNSON
Dated: September 12, 2000 By /s/ M. Ullmann
--------------------------------
Name: Michael Ullmann
Title: Secretary
JOHNSON & JOHNSON DEVELOPMENT
CORPORATION
Dated: September 12, 2000 By /s/ J. J. Bergin
--------------------------------
Name: James J. Bergin
Title: Assistant Secretary
